An experimental Eli Lilly (LLY 3.26 %) & Co. lung-cancer drug hasn’t reached the market, but some doctors are already arguing its price should be below average because the drug […]

A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held […]

The big worries on growth hanging over the pharmaceuticals industry are poles apart. Pressure on U.S. drug pricing is casting a shadow over the sector’s most lucrative market. But slowing […]

By David Beier, John Osborn and Merv Turner A familiar trope employed at the climax of movie thrillers is the zombie who returns from the dead to devour the brains […]

Last week, Dr. Pearl kicked off a three-part series on the physician experience. His first installment revealed Why This Is The Best Of Times To Be A Physician In America. […]

Amgen Inc. raised its 2015 guidance after reporting that its second-quarter earnings rose 6.9% on better-than-expected sales growth and lower operating expenses. For the year, the biotechnology company now expects […]

What do you get when you combine Obamacare with an expected explosion in the use of pricey drugs and the rapid aging of the Baby Boomer population? The answer, courtesy […]

The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or […]

Today’s announcement that health insurer Anthem plans to spend $54 billion to buy its rival, Cigna, to create the largest health insurance country in America is a good time to […]

An appeals court ruled that Novartis AG could begin the first U.S. sales of a knockoff biotech drug on Sept. 2, a key step in efforts to contain spending on […]